Oxford Biomedica, Homology Medicines Enter Deal To Expand Viral Vector Offerings


London-listed cell and gene therapy Oxford Biomedica Plc OXBDF said it would form a viral vector manufacturing business with Homology Medicines Inc FIXX.

  • Oxford Biomedica Solutions' Adeno-Associated Virus (AAV) Manufacturing and Innovation Business will be led by Tim Kelly as CEO and Chair of its Board of Directors. 
  • Kelly is currently the Chief Operating Officer of Homology.
  • Oxford will pay Homology $130 million upfront and invest $50 million to fund Oxford Biomedica Solutions in return for an 80% stake.
  • Homology will own 20% of the new company. The transaction is expected to close in Q1 2022.
  • Oxford Biomedica said the venture would broaden its offerings with Homology's expertise in adeno-associated virus manufacturing. 
  • Price Action: FIXX shares are down 2.31% at $2.96 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareContractsSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!